Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.04−0.55 (-1.92%)
Close on Nov 17, 2026Market cap $2.20BP/E –Yield –
Celldex Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Celldex Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$325.83M. For fiscal 2025 it was -$287.37M. The highest annual figure on record is -$6.46M in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$287.37M | – |
| FY2024 | Dec 31, 2024 | -$195.08M | – |
| FY2023 | Dec 31, 2023 | -$154.54M | – |
| FY2022 | Dec 31, 2022 | -$115.23M | – |
| FY2021 | Dec 31, 2021 | -$71.24M | – |
| FY2020 | Dec 31, 2020 | -$63.35M | – |
| FY2019 | Dec 31, 2019 | -$55.03M | – |
| FY2018 | Dec 31, 2018 | -$156.44M | – |
| FY2017 | Dec 31, 2017 | -$121.53M | – |
| FY2016 | Dec 31, 2016 | -$132.92M | – |
| FY2015 | Dec 31, 2015 | -$129.54M | – |
| FY2014 | Dec 31, 2014 | -$122.43M | – |
| FY2013 | Dec 31, 2013 | -$81.44M | – |
| FY2012 | Dec 31, 2012 | -$58.08M | – |
| FY2011 | Dec 31, 2011 | -$43.40M | – |
| FY2010 | Dec 31, 2010 | -$6.46M | – |
| FY2009 | Dec 31, 2009 | -$36.85M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$80.62M | – |
| Q1 FY2026 | Mar 31, 2026 | -$84.44M | – |
| Q4 FY2025 | Dec 31, 2025 | -$87.15M | – |
| Q3 FY2025 | Sep 30, 2025 | -$73.62M | – |
| Q2 FY2025 | Jun 30, 2025 | -$63.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -$62.74M | – |
| Q4 FY2024 | Dec 31, 2024 | -$56.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$52.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$46.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$40.61M | – |
| Q4 FY2023 | Dec 31, 2023 | -$47.63M | – |
| Q3 FY2023 | Sep 30, 2023 | -$41.24M | – |
| Q2 FY2023 | Jun 30, 2023 | -$33.21M | – |
| Q1 FY2023 | Mar 31, 2023 | -$32.47M | – |
| Q4 FY2022 | Dec 31, 2022 | -$27.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$27.70M | – |
| Q2 FY2022 | Jun 30, 2022 | -$36.40M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.26M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.34M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.82M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.44M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.64M | – |
| Q4 FY2020 | Dec 31, 2020 | -$24.78M | – |
| Q3 FY2020 | Sep 30, 2020 | -$14.34M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.37M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.87M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.99M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.84M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.26M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.94M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.12M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.76M | – |
| Q2 FY2018 | Jun 30, 2018 | -$16.87M | – |
| Q1 FY2018 | Mar 31, 2018 | -$119.68M | – |
| Q4 FY2017 | Dec 31, 2017 | -$25.53M | – |
| Q3 FY2017 | Sep 30, 2017 | -$31.96M | – |
| Q2 FY2017 | Jun 30, 2017 | -$28.93M | – |
| Q1 FY2017 | Mar 31, 2017 | -$35.11M | – |
| Q4 FY2016 | Dec 31, 2016 | -$34.85M | – |
| Q3 FY2016 | Sep 30, 2016 | -$29.99M | – |
See a number that looks wrong?